NEURAL

THERAPEUTICS

WHO WE ARE

Neural Therapeutics Inc. is an ethnobotanical drug discovery/development company focused on developing products and conducting research with psychoactive plants, the first being a cactus commonly known as San Pedro (Echinopsis pachanoi) containing mescaline.

WHO WE ARE

Neural Therapeutics Inc. is an ethnobotanical drug discovery/development company focused on developing products and conducting research with psychoactive plants, the first being a cactus commonly known as San Pedro (Echinopsis pachanoi) containing mescaline.

OUR GOAL

Neural Therapeutics Inc. aims to find where the historical use in traditional medicine has proven to be effective and capitalize on the opportunities that can be applied in today’s Nutraceutical and Pharmaceutical markets.

OUR GOAL

Neural Therapeutics Inc. aims to find where the historical use in traditional medicine has proven to be effective and capitalize on the opportunities that can be applied in today’s Nutraceutical and Pharmaceutical markets.

HISTORY

We believe that nearly six thousand years of indigenous experience provides an invaluable source of information that unlocks the key to the capabilities of the whole plant extract. We strive to honor native traditions and treat the San Pedro plant as a source of medicine that the nature has provided.

HISTORY

We believe that nearly six thousand years of indigenous experience provides an invaluable source of information that unlocks the key to the capabilities of the whole plant extract. We strive to honor native traditions and treat the San Pedro plant as a source of medicine that the nature has provided.

HOW WE CAN HELP

Mental health issues are at the forefront of our concern as we see a surge in conditions like anxiety, depression, and substance abuse. Naturally extracted Mescaline, accompanied by other compounds, has demonstrated significant advantages when compared to current pharmaceuticals. We believe that medical practitioners and therapists will need all “tools” possible.

OUR ROADMAP

We begin with a common R&D process that branches into two paths developing pharmaceuticals and nutraceuticals with the aim of utilizing the entire plant and creating zero waste.

OUR ROADMAP

We begin with a common R&D process that branches into two paths developing pharmaceuticals and nutraceuticals with the aim of utilizing the entire plant and creating zero waste.

PROPOSED LEADERSHIP AND ADVISORY TEAM

IAN CAMPBELL, MSc

CHIEF EXECUTIVE OFFICER AND DIRECTOR

Mr. Campbell is an executive leader with an international reputation in the US, Canada, and Czech Republic for his work in the fields of environmental science and pharmacology.

DR. JASON DYCK, PHD.

INDEPENDENT DIRECTOR AND ADVISORY BOARD MEMBER

Dr. Dyck is a renowned scientist and professor with 30+ years of experience studying heart disease and pathogenesis of heart defects.

DR. KELLY NARINE, PHD.

INDEPENDENT DIRECTOR AND ADVISORY BOARD MEMBER

Dr. Narine has her PhD in Medical Genetics and is the former Vice President of Global Research & Medical Affairs at Aurora Cannabis Inc.

IAN CAMPBELL, MSc

CHIEF EXECUTIVE OFFICER
AND DIRECTOR

Mr. Campbell is an executive leader with an international reputation in the US, Canada, and Czech Republic for his work in the fields of environmental science and pharmacology.

DR. JASON DYCK, PHD.

INDEPENDENT DIRECTOR AND ADVISORY BOARD MEMBER

Dr. Dyck is a renowned scientist and professor with 30+ years of experience studying heart disease and pathogenesis of heart defects.

DR. KELLY NARINE, PHD.

INDEPENDENT DIRECTOR AND ADVISORY BOARD MEMBER

Dr. Narine has her PhD in Medical Genetics and is the former Vice President of Global Research & Medical Affairs at Aurora Cannabis Inc.

JOHN DURFY, CFA, CPA, MBA

DIRECTOR

Mr. Durfy is currently a CEO and Director of High Fusion Inc. Over the past 30 years he has honed his executive experience in operations, investment management, and financial and business strategy.

COLIN MCLELLAND, CPA, CA, CFA

INDEPENDENT DIRECTOR

Mr. McLelland started his business career as an accountant at Ernst & Young LLP before moving into mid-market investment banking.

ROBERT WILSON

CHIEF FINANCIAL OFFICER

Mr. Wilson’s past leadership in corporate finance, investor relations, governance, financial and regulatory reporting, and mergers and acquisitions has led him to his current role as the Chief Financial Officer of High Fusion Inc.

JOHN DURFY, CFA, CPA, MBA

DIRECTOR

Mr. Durfy is currently a CEO and Director of High Fusion Inc. Over the past 30 years he has honed his executive experience in operations, investment management, and financial and business strategy.

COLIN MCLELLAND, CPA, CA, CFA

INDEPENDENT DIRECTOR

Mr. McLelland started his business career as an accountant at Ernst & Young LLP before moving into mid-market investment banking.

Omar Gonzalez

CHIEF FINANCIAL OFFICER

Mr. Gonzalez has over 20 years’ experience in audit & assurance in South America, included 5 years of public and private audit practice, financial analysis, and corporate development in Canada.

PROFESSOR DAVID NUTT

Scientific Advisory Board Member

David Nutt is a psychiatrist and the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science at the Imperial College London.

DR. CORNELIA (NEL) WIEMAN

Dr. Wieman has 20+ years of psychiatric experience and is a leader in Indigenous health and medical education.

DR. DUKE FU

Scientific Advisory Board Member

Dr. Fu is one of the few Board-certified Nuclear Pharmacists (BCNP) in the State of Nevada and has extensive experience with mycology.

PROFESSOR DAVID NUTT

Scientific Advisory Board Member

David Nutt is a psychiatrist and the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science at the Imperial College London.

DR. DUKE FU

Scientific Advisory Board Member

Dr. Fu is one of the few Board-certified Nuclear Pharmacists (BCNP) in the State of Nevada and has extensive experience with mycology.

INTERESTED IN DOWNLOADING OUR INVESTOR PACKAGE?

Please provide your email to get a download link for our corporate deck.

PRESS RELEASES